Livingston firm aims for global market reach in next generation biosensors and wearables through French partnership
A Livingston-based medical diagnostics specialist has teamed up with a French manufacturer of advanced electrodes to develop next generation biosensors and wearables.
FlexMedical aims to revolutionise ‘point-of-care’ medical testing kits to speed up the diagnosis of multiple diseases and medical conditions – including respiratory disease, sepsis, kidney disease, heart disease and diabetes.
It is partnering with Linxens, a global leader in the electronics industry, with seven R&D centres and eight factories, employing over 3,000 people worldwide, with a head office near Paris.
The strategic collaboration will open up opportunities to develop and commercialise electrode components for diagnostic devices used in the healthcare industry, say the firms.
Kevin Fallon, FlexMedical’s CEO and co-founder, said: “The partnership with Linxens opens up the point-of-care testing market in North America and Asia, as we continue to internationalise the business we founded a decade ago.
“The diagnostics industry has changed post COVID, wearable technology has risen up the agenda, along with AI having an increasing impact, and we think the collaboration with Linxens will keep us ahead of the curve while significantly improving our market reach.”
Minh Le, vice-president of Linxens Healthcare, added: “This collaboration expands our biosensor portfolio by integrating functionalisation capabilities, enabling us to deliver end-to-end solutions – from flex-PCB or printed electrodes to fully functional sensor platforms. Together, we streamline the journey from R&D to mass production, accelerating the delivery of innovative diagnostic solutions.”
FlexMedical is a contract design, development, and manufacturing organisation working with a range of clients from early stage university spinouts to multinational original equipment manufacturers (OEMs), specialising in diagnostics and biosensors, including wearable technologies.
Directors Murray Whyte and Donogh FitzGerald will take up new roles in the company’s leadership team, with Whyte moving from CTO to the newly created position of chief growth officer, with FitzGerald switching to CTO from chief science officer. FlexMedical is also planning to hire a technical director and product developers across science and engineering.
You can read the original article on FutureScot here.